Drug Approval | April 18, 2022
Amneal achieves second U.S. biosimilars approval with Alymsys
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
The initial courses of Lap. Hernia Masterclass will encompass commonly performed hernia procedures
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
It paves the way for an industry Code of Good Practice
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
The science leader comes with a rich experience in the employment testing industry
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Subscribe To Our Newsletter & Stay Updated
